- Home
- CSTL vs PRAA Comparison
CSTL vs PRAA Comparison
Compare CSTL & PRAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- PRAA
- Stock Information
- Founded
- CSTL 2007
- PRAA 1996
- Country
- CSTL United States
- PRAA United States
- Employees
- CSTL N/A
- PRAA N/A
- Industry
- CSTL Medical Specialities
- PRAA Finance: Consumer Services
- Sector
- CSTL Health Care
- PRAA Finance
- Exchange
- CSTL Nasdaq
- PRAA Nasdaq
- Market Cap
- CSTL 848.1M
- PRAA 834.7M
- IPO Year
- CSTL 2019
- PRAA N/A
- Fundamental
- Price
- CSTL $25.75
- PRAA $22.57
- Analyst Decision
- CSTL Strong Buy
- PRAA Strong Buy
- Analyst Count
- CSTL 6
- PRAA 2
- Target Price
- CSTL $40.33
- PRAA $32.00
- AVG Volume (30 Days)
- CSTL 358.8K
- PRAA 218.4K
- Earning Date
- CSTL 02-27-2025
- PRAA 02-19-2025
- Dividend Yield
- CSTL N/A
- PRAA N/A
- EPS Growth
- CSTL N/A
- PRAA N/A
- EPS
- CSTL 0.21
- PRAA 1.79
- Revenue
- CSTL $311,878,000.00
- PRAA $1,114,524,000.00
- Revenue This Year
- CSTL $51.99
- PRAA $39.43
- Revenue Next Year
- CSTL N/A
- PRAA $6.61
- P/E Ratio
- CSTL $122.41
- PRAA $12.61
- Revenue Growth
- CSTL 62.43
- PRAA 38.87
- 52 Week Low
- CSTL $16.97
- PRAA $18.64
- 52 Week High
- CSTL $35.84
- PRAA $28.64
- Technical
- Relative Strength Index (RSI)
- CSTL 37.34
- PRAA 50.71
- Support Level
- CSTL $26.65
- PRAA $21.62
- Resistance Level
- CSTL $28.48
- PRAA $23.97
- Average True Range (ATR)
- CSTL 1.12
- PRAA 0.81
- MACD
- CSTL -0.17
- PRAA -0.07
- Stochastic Oscillator
- CSTL 0.94
- PRAA 50.70
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.